Posts by: Alberto Molano, PhD

Alberto Molano, PhD

Alberto Molano was born in Bogotá, Colombia. He studied medicine at Universidad del Rosario and obtained a Ph.D. in Immunology from Weill Cornell Graduate School of Medical Sciences in New York. He conducted research and authored or co-authored twenty publications on molecular and cellular immunology, autoimmunity, immunology of aging and parasite immunology.

July 15, 2019July 15, 2019

IPF Patients in Spain, Other Countries Share Similar Characteristics to Allow Comparison and Pooling, Study Suggests

News

The demographic and clinical characteristics of patients with idiopathic pulmonary fibrosis (IPF) in Spain are similar to those of IPF patients in other countries, allowing for comparison with other ... Read more

July 1, 2019July 1, 2019

Gli Proteins Linked to Promotion of Lung Fibrosis by Impact on Fibroblasts, Lab Study Shows

News

Gli proteins can trigger fibroblast activation and support their role in promoting fibrosis in the lungs in response to damage to the airspaces, a study in mice shows. The ... Read more

June 11, 2019June 11, 2019

Funding Secured for Phase 1 Trial of Potential IPF Treatment LTI-03

News

Lung Therapeutics announced that it has raised $36 million in Series C financing to fund two projects, including a healthy volunteer Phase 1 clinical trial testing LTI-03, an experimental ... Read more

May 20, 2019May 20, 2019

Exhalative Breath Biomarkers Not Useful to Distinguish Among Different ILDs, Study Reports

News

Measuring three specific biomarkers — nitric oxide, PGE2, and 8‐isoprostane — in the exhaled breath condensates (EBC) or bronchoalveolar lavage fluids (BALF) of patients with different forms of interstitial ... Read more

May 3, 2019May 3, 2019

AstraZeneca Turns to Artificial Intelligence to Speed Discovery of New Medicines for IPF

News

A long-term collaboration was announced to accelerate the discovery of new medicines for idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD) by combining BenevolentAI’s expertise in artificial intelligence ... Read more

February 26, 2019March 5, 2019

Algernon Plans to Test Its Lead Anti-fibrotic Compound in Animal Study of IPF

News

Algernon Pharmaceuticals announced its plans to conduct a new in vivo animal study comparing its lead anti-fibrotic NP-251 compound with clinically relevant doses of both Esbriet (pirfenidone) and Ofev (nintedanib), two approved medicines for the treatment ... Read more

October 31, 2018October 31, 2018

Lung Cancer Has High Incidence, Worse Prognosis Among IPF Patients, Study Finds

News

The incidence of lung cancer is greater among patients with idiopathic pulmonary fibrosis (IPF), compared with the general population, and is associated with a worse prognosis, a new U.S. study ... Read more

Pin It on Pinterest